ONKT-103

N/A

Report date: 2025/05/08 16:35:27

Base Information

Drug NameONKT-103

Drug Alias NameONKT-103

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsMucin-1 inhibitors

TargetsMucin-1

Therapy Area/IndicationsOvarian NeoplasmsPancreatic NeoplasmsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIreland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesONK Therapeutics Ltd

China Registration ClassN/A

Develop Information

Active CompaniesONK Therapeutics Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsPancreatic NeoplasmsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A